, Prise en charge médicale des personnes vivant avec le VIH-recommandations du groupe d'experts, Sous la Direction du Professeur Philippe Morlat et sous l'égide du CNS et de l'ANRS. Actualisation, CNS Conseil National du SIDA et des hépatites virales, 2013.

M. J. Friedrich, WHO updates HIV treatment and prevention guideline, JAMA, vol.314, 2014.

C. Lewden, V. Bouteloup, D. Wit, S. Sabin, C. Mocroft et al., All-cause mortality in treated HIV-infected adults with CD4 ? 500/mm 3 compared with the general population: evidence from a large European observational cohort collaboration, Int J Epidemiol, vol.41, pp.433-478, 2012.

H. B. Krentz and M. J. Gill, The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients, AIDS Patient Care STDs, vol.30, pp.11-18, 2016.

V. Supervie and D. Ekouevi, Overview of the HIV epidemics in France and worldwide, Rev Prat, vol.64, pp.1060-1066, 2014.

M. Trapero-bertran and J. Oliva-moreno, Economic impact of HIV/ AIDS: a systematic review in five European countries, Health Econ Rev

C. E. Sloan, K. Champenois, P. Choisy, E. Losina, R. P. Walensky et al., Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults, AIDS Lond Engl, vol.26, p.45, 2012.

N. I. Paton, W. Stöhr, A. Arenas-pinto, M. Fisher, I. Williams et al., Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial, Lancet HIV, vol.2, pp.417-443, 2015.

J. Meynard, V. Bouteloup, R. Landman, P. Bonnard, V. Baillat et al., Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial, J Antimicrob Chemother, vol.65, pp.2436-2480, 2010.

J. Arribas, P. Girard, P. N. Winston, A. Marcelin, A. Elbirt et al., Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomised trials, HIV Med, vol.17, pp.358-67, 2015.

J. Meynard, L. Moinot, R. Landman, L. Morand-joubert, A. Besseghir et al., Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomised non

, J Antimicrob Chemother, vol.73, pp.1672-1678, 2018.

A. Hermes, K. Squires, L. Fredrick, M. Martinez, M. Pasley et al., Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women, HIV Clin Trials, vol.13, pp.308-331, 2012.

P. Cahn, J. Montaner, P. Junod, P. Patterson, A. Krolewiecki et al., randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1st PI-based regimen, PLoS ONE (Internet), vol.6, p.23726, 2011.

J. Gathe, B. A. Da-silva, D. E. Cohen, M. R. Loutfy, D. Podzamczer et al., A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks, J Acquir Immune Defic Syndr, issue.50, pp.474-81, 1999.

U. Restelli, D. Croce, E. Porazzi, F. Scolari, M. Bonfanti et al., Health technology assessment in the HIV setting: the case of monotherapy, New Microbiol, vol.37, pp.247-61, 2014.

L. Oddershede, S. Walker, W. Stöhr, D. T. Dunn, A. Arenas-pinto et al., Cost effectiveness of protease inhibitor monotherapy versus standard triple therapy in the long-term management of HIV patients: analysis using evidence from the PIVOT trial, PharmacoEconomics, vol.34, pp.795-804, 2016.

B. Gazzard, A. Hill, and A. Anceau, Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices, Appl Health Econ Health Policy, vol.9, pp.217-240, 2011.

, Prise en charge médicale des personnes vivant avec le VIH-recommandations du groupe d'experts, Sous la Direction du Professeur Philippe Morlat et sous l'égide du CNS et de l'ANRS. Optimisation d'un traitement antirétroviral en situation de succès virologique (Internet), CNS Conseil National du SIDA et des hépatites virales, 2017.

M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, Methods for the economic evaluation of health care programmes, 2015.

, A methodological guide: choices in methods for economic evaluation (Internet), 2012.

, Ministère des Affaires sociales et de la Santé

, Sécurité Sociale l'Assurance Maladie. Statistiques et publications (Internet), 2015.

, Caisse nationale de l'assurance maladie. Document de travail, p.2014

, International Monetary Fund: World Economic Outlook Database, 2016.

J. Ware, M. Kosinski, D. Turner-bowker, M. Sundaram, B. Gandek et al., User's manual for the SF-12v2 health survey, 2009.

, Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting, BMJ, vol.342, p.1548, 2011.

H. A. Glick, J. A. Doshi, S. S. Sonnad, and D. Polsky, Economic evaluation in clinical trials, 2014.

A. M. Gray, P. M. Clarke, J. L. Wolstenholme, and S. Wordsworth, Applied methods of cost-effectiveness analysis in healthcare, 2011.

J. D. Sachs, Macroeconomics and health: investing in health for economic development, Rev Panam Salud Pública, vol.12, pp.143-147, 2002.

M. Lothgren and N. Zethraeus, Definition, interpretation and calculation of cost-effectiveness acceptability curves, Health Econ, vol.9, pp.623-653, 2000.

W. G. Manning and J. Mullahy, Estimating log models: to transform or not to transform?, J Health Econ, vol.20, pp.461-94, 2001.

A. Briggs, M. Sculpher, and K. Claxton, Decision modelling for health economic evaluation, 2006.

E. Fenwick, D. A. Marshall, A. R. Levy, and G. Nichol, Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation, BMC Health Serv Res, vol.6, p.52, 2006.

S. Lambert-niclot, M. Grude, J. Meynard, A. Marcelin, M. Valantin et al., Ultrasensitive human immunodeficiency virus type 1 viral load as a marker of treatment choice for simplification strategies, Clin Infect Dis, vol.67, pp.1883-1892, 2018.

E. Papot, R. Landman, F. Louni, C. Charpentier, G. Peytavin et al., Budget impact of antiretroviral therapy in a French clinic cohort, AIDS, vol.31, pp.1271-1280, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01966749

T. Delate and S. J. Coons, The discriminative ability of the 12-Item short form health survey (SF-12) in a sample of persons infected with HIV, Clin Ther, vol.22, pp.1112-1132, 2000.